Tumor growth and chemo response may be predicted by mathematical modelMay 19, 2009The aggressiveness of tumors and their susceptibility to chemotherapy may become easier to predict based on a mathematical model developed at The University of Texas Health Science Center at Houston. In spite of extensive experimental and clinical studies, the process of cancer growth is not well understood. Tumors are complex systems, with changes at the molecular and cellular levels influencing shape and behavior in sometimes unpredictable ways. New research by a scientist in mathematical oncology at the UT Health Science Center at Houston suggests that mathematical modeling based on data from the molecular and cellular levels could shed light on tumor development and lead to better treatments. Cancer is the second most common cause of death in the United States, exceeded only by heart disease, according to the American Cancer Society. At the 100th annual meeting of the American Association for Cancer Research in Denver this spring, Vittorio Cristini, Ph.D., an associate professor of health informatics at The University of Texas School of Health Information Sciences at Houston, demonstrated the predictability of tumor growth in brain cancer and chemotherapy response in breast cancer. Findings appear in two different papers in the May 15 print issue of the association's peer-reviewed journal Cancer Research. The mathematical model developed by Cristini's lab works by defining tumor biologic and molecular properties relating to laboratory and clinical observations of cancers. In this model, the behavior of cancer cells and their surroundings is linked to tumor growth, shape and treatment response. "The central finding of this work is that tumor growth and invasion are not erratic or unpredictable, or solely explained through genomic and molecular events, but rather are predictable processes obeying biophysical laws," the authors wrote in the paper addressing predictability of tumor growth in brain cancer. Tumors obtain nutrients and oxygen by harnessing the surrounding blood vessels and making new vessels. Since there typically aren't enough nutrients and oxygen to support tumor cells, an uneven distribution of these substances is created inside and around the tumor mass, Cristini said. The research of Cristini and colleagues, who worked in collaboration with Elaine L. Bearer, M.D., Ph.D., professor at the Brown School of Medicine, suggests that tumor growth and invasion could be predicted by using biophysical laws that link the effects of the uneven distribution of cell nutrients and oxygen to overall tumor behavior. For different values of the input parameters, the model consistently reproduced the patterns of tumor invasion observed in experiments and in patient tumors, Cristini said. The patterns were regulated by changes in cellular characteristics, causing more aggressive tumor cells to invade the healthy tissue. As cancer cells invade and replicate themselves, they make the tumor shape unstable and more invasive. The model correctly predicted the different types of invasion under a variety of conditions. The model further predicted that the different forms of cancer invasion correspond to different stages of tumor progression, Cristini said. In regions of low oxygen, these changes may include a slowdown in cell replication and heightened cell migration, which can result in a "single-cell file" invasion pattern. As cells aggregate in regions that have better access to nutrients and oxygen, migration is lessened and cell replication is resumed. This leads to the formation of wave-like patterns of cell rearrangements at the tumor boundary and the formation of round infiltrative "fingers" that can detach from the tumor as clusters of cells. In the second paper, working in collaboration with Mary Edgerton, M.D., Ph.D., associate professor of pathology at The University of Texas M. D. Anderson Cancer Center, the researchers used the mathematical model to successfully predict the effects of doxorubicin on breast tumor growth. The model incorporates information gleaned from cancer cells grown in the laboratory to determine whether a prescribed drug will reach the tumor in sufficient quantities to kill the malignant cells. "We seek to improve the precision of prescribing chemotherapeutic drugs, since it is sometimes hard to tell which will work and which will not, and what the optimal dose is for a particular patient," said Hermann Frieboes, Ph.D., lead author of the chemotherapy study and a post doctoral fellow at the UT School of Health Information Sciences. In the not-too-distant future, the mathematical model could help design therapies in which the molecular and cellular characteristics of a patient's tumor are manipulated, Cristini said. This could decrease the spread of the tumor and help surgeons remove growths more effectively. This manipulation could also increase the susceptibility of tumors to chemotherapy, he added. The model could augment efforts to predict drug response, which currently include removing a tiny sample of cancer tissue and testing the response of its cells to cancer drugs in a laboratory situation before the patient starts treatment. By basing the model input parameters on specific patient data, the treatment outcomes could be predicted better. The two studies, titled "Multiparameter computational modeling of tumor invasion" and "Prediction of drug response in breast cancer using integrative experimental/computational modeling," received support from The Cullen Trust for Health Care, the National Science Foundation, the National Institutes of Health and the U.S. Department of Defense. Cristini's co-authors also include Mauro Ferrari, Ph.D., director of the nanomedicine division at the UT Health Science Center at Houston and president of the Alliance for NanoHealth, Houston; and two members of the faculty of the University of California, Irvine, John Lowengrub, Ph.D., and John Fruehauf, M.D., Ph.D. UT Health Science Center at Houston |
|||||||||||||||||||||
| Related Tumor Growth Current Events and Tumor Growth News Articles Laser therapy can aggravate skin cancer High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Common pain relief medication may encourage cancer growth Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Cancers' Sweet Tooth May Be Weakness The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered. Researchers 'notch' a victory toward new kind of cancer drug Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. New mechanism explains how the body prevents formation of blood vessels Researchers at Uppsala University, in collaboration with colleagues in Sweden and abroad, have identified an entirely new mechanism by which a specific protein in the body inhibits formation of new blood vessels. CSHL study shows that some malignant tumors can be shut down after all Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. Hundreds of genes distinguish patients likely to survive advanced melanoma Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. Early-stage, HER2-positive breast cancer patients at increased risk of recurrence Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. Researchers use drug-radiation combo to eradicate lung cancer Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. More Tumor Growth Current Events and Tumor Growth News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||